MEDISTAT 1.25 NASAL SPRAY

MEDISTAT 1.25 NASAL SPRAY is safe if used at prescribed doses for the prescribed duration as advised by your doctor

Yes, MEDISTAT 1.25 NASAL SPRAY is a controlled substance

Yes, MEDISTAT 1.25 NASAL SPRAY a sedative medication used before and during diagnostic or surgical procedures either in combination with or without local anesthesia

Yes, MEDISTAT 1.25 NASAL SPRAY belongs to benzodiazepine class of sedative medication

No, MEDISTAT 1.25 NASAL SPRAY does not have any analgesic properties. It is used as a central nervous system depressant that slows brain activity, causes relaxation and induces sleep (anesthetic)

Yes, MEDISTAT 1.25 NASAL SPRAY causes retrograde amnesia (short term loss of memory)

Medistat 1.25 nasal spray is a prescription medicine that contains midazolam 1.25 mg, a short-acting benzodiazepine. It is formulated for intranasal administration, meaning it is sprayed into the nostril where the drug is absorbed through the nasal mucosa into the bloodstream. Midazolam acts on the central nervous system to produce sedative, anxiolytic, muscle-relaxant, and anticonvulsant effects. The exact approved indications and usage instructions for Medistat 1.25 may differ between countries, so it should be used only as directed by a healthcare professional.

Medistat 1.25 nasal spray is generally used in clinical practice where rapid onset of sedative or anticonvulsant action is needed and intravenous access may be difficult. Intranasal midazolam can be used as part of procedural sedation, premedication before minor diagnostic or therapeutic procedures, or for acute management of certain seizure emergencies, depending on local regulatory approvals and specialist guidance. The specific indication for an individual patient should be determined by the prescribing physician, who will consider the patient’s age, clinical condition, and overall treatment plan.

Medistat 1.25 nasal spray must be used exactly as instructed by a doctor or other qualified healthcare professional. The prescriber will explain which nostril to use, how many sprays to administer, and under what circumstances it should be given. Because midazolam is a potent sedative that can depress breathing, it should not be used more frequently or in higher amounts than prescribed. The user or caregiver should be trained in the correct technique for intranasal administration and in recognizing signs of excessive sedation or respiratory difficulty that require urgent medical attention. Do not attempt to determine your own dose or dosing schedule.

Common side effects of Medistat 1.25 nasal spray are related to both the nasal route and the central nervous system effects of midazolam. These may include nasal irritation, burning or discomfort in the nose, runny nose, unpleasant taste, drowsiness, dizziness, fatigue, headache, and reduced alertness. Some people may experience temporary problems with memory or concentration after administration. These effects are usually short-lived but can be more pronounced in older adults or in people who are sensitive to benzodiazepines. If side effects are severe, persistent, or concerning, medical advice should be sought.

Serious risks with Medistat 1.25 nasal spray are mainly related to excessive central nervous system depression. These include profound sedation, respiratory depression (slow or shallow breathing), low blood pressure, decreased oxygen levels, and, in extreme cases, cardiorespiratory arrest. The risk is higher in older adults, people with pre-existing respiratory or cardiac disease, those with severe liver impairment, and patients taking other central nervous system depressants such as opioids, alcohol, or certain sleep or anxiety medicines. Paradoxical reactions such as agitation, restlessness, or aggressive behaviour can also occur, particularly in children or older adults. Any signs of breathing difficulty, bluish lips, inability to stay awake, or collapse require immediate emergency medical care.

Use of Medistat 1.25 nasal spray in children depends on local regulatory approvals and specialist recommendations. Intranasal midazolam is sometimes used in paediatric settings for procedural sedation or acute seizure management, but dosing and administration must be carefully tailored to the child’s age and weight and supervised by clinicians experienced in paediatric sedation or epilepsy care. Parents or caregivers should never use Medistat 1.25 in a child without explicit instructions from a paediatrician or paediatric specialist, and they should be trained in when and how to administer the medicine and when to seek emergency help.

Midazolam, the active ingredient in Medistat 1.25 nasal spray, is a benzodiazepine and can lead to tolerance, physical dependence, and misuse if used repeatedly or for prolonged periods, especially at higher cumulative doses. For this reason, it is usually classified as a controlled substance. In many clinical scenarios, intranasal midazolam is used intermittently or as a single-dose treatment, which reduces but does not eliminate the risk of dependence. Patients with a history of substance use disorder or misuse of sedatives, alcohol, or opioids should be carefully evaluated before midazolam is prescribed. Medistat 1.25 should never be shared with others or used for non-medical purposes.

No. Medistat 1.25 nasal spray can cause significant drowsiness, slowed reaction time, impaired coordination, and reduced judgment. These effects can persist for several hours after administration and may be prolonged in older adults, people with liver impairment, or those taking other central nervous system depressants. Driving, operating machinery, or performing tasks that require full alertness should be strictly avoided until the sedative effects have completely worn off and a healthcare professional confirms that it is safe to resume such activities.

Medistat 1.25 nasal spray should not be used together with alcohol or other sedative or centrally acting medicines unless specifically directed and closely supervised by a doctor. Alcohol, opioids, certain antidepressants, antipsychotics, antihistamines, and other benzodiazepines can enhance the sedative and respiratory-depressant effects of midazolam, greatly increasing the risk of dangerous side effects, including severe drowsiness, breathing problems, low blood pressure, and loss of consciousness. Patients should inform their doctor about all medicines and substances they use, including over-the-counter products and herbal supplements, so that potential interactions can be assessed.

If Medistat 1.25 nasal spray appears ineffective or symptoms such as agitation, pain, or seizures persist after administration, follow the action plan provided by your healthcare professional. Do not give additional doses or repeat administration on your own unless this has been clearly specified in your doctor’s written instructions. In many situations, persistent symptoms or lack of response should prompt immediate medical review or emergency care, especially if the medicine was used for a seizure emergency or procedural sedation. Bring the product packaging and any written treatment plan with you when seeking urgent medical help so that clinicians can understand exactly what has been given.

Medistat 1.25 nasal spray should be stored according to the instructions on the package insert, typically at room temperature away from excessive heat, moisture, and direct light, and out of the reach and sight of children. Because midazolam is a controlled substance, the spray should be kept in a secure place to prevent accidental use or misuse by others. Do not use the product after the expiry date printed on the label. Any unused or expired spray should be disposed of safely, following local regulations or pharmacy guidance. Do not throw it into household waste or wastewater unless advised that this is acceptable in your area.